Tvardi Therapeutics files for up to $9.7 million more in at-the-market stock sales

Tvardi Therapeutics, Inc. filed a prospectus supplement dated July 17, 2026 for an at-the-market offering of up to $9,689,765 in common stock through its sales agent, JonesTrading Institutional Services LLC. The company previously entered into a Capital on Demand Sales Agreement with Jones and may offer shares from time to time having an aggregate gross sales price of up to $9,689,765.¹

This follows an earlier prospectus. Tvardi had previously filed a prospectus dated May 12, 2026 covering up to $12,500,000 in stock sales under the same agreement, under which no additional shares will be sold after this new filing, and the company had sold 3,110,769 shares for approximately $11.0 million in gross proceeds.¹

Tvardi's common stock trades on Nasdaq under the symbol TVRD, and closed at $3.08 per share on July 16, 2026.¹ Jones is entitled to a commission of up to 3.0% of gross proceeds from shares sold under the agreement.¹

The company said it intends to use net proceeds for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses and capital expenditures.¹

On the clinical side, Tvardi is developing STAT3 inhibitors TTI-101 and TTI-109. TTI-101 is in Phase 1b/2 development in hepatocellular carcinoma.¹ The company reported positive topline data in July 2026 from a TTI-109 Phase 1 trial, which confirmed rapid prodrug conversion, dose-proportional pharmacokinetics with exposures above the STAT3 IC50, and reductions of up to 60% in STAT3-driven immune cell populations in exploratory analysis.¹ In October 2025, the company reported preliminary Phase 2 data of TTI-101 in idiopathic pulmonary fibrosis and concluded the study did not meet its goals.¹